1. Inicio
  2. Proyectos y Estudios
  3. ENSAYO DE DOSIS RESPUESTA, MULTICÉNTRICO, DOBLE CIEGO, ALEATORIZADO Y CONTROLADO CON PLACEBO DE YKP3089 COMO TRATAMIENTO COMPLEMENTARIO EN SUJETOS CON CRISIS DE INICIO PARCIAL, CON UNA EXTENSIÓN ABIERTA OPCIONAL.

ENSAYO DE DOSIS RESPUESTA, MULTICÉNTRICO, DOBLE CIEGO, ALEATORIZADO Y CONTROLADO CON PLACEBO DE YKP3089 COMO TRATAMIENTO COMPLEMENTARIO EN SUJETOS CON CRISIS DE INICIO PARCIAL, CON UNA EXTENSIÓN ABIERTA OPCIONAL.

Datos básicos

Código:
YKP3089C017
Protocolo:
YKP3089C017
EUDRACT:
2013-001858-10
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2013
Año de finalización:
2016
ENSAYO CLÍNICO INTERNACIONAL

Documentos

  • No hay documentos

Participantes

Financiadores - Promotores

SK LIFE SCIENCE, INC.

Resultados del Ensayo Clínico

[Farewell open letter to SEFH members].

Poveda Andrés JL

Editorial Material. 10.7399/fh.2015.39.6.10128. 2015


[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence

Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda

Editorial Material. 10.1016/j.farma.2024.08.009. 2024

  • Open Access.

[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Andrés JLP, Solsona MDE

Article. 10.1016/j.farma.2023.10.004. 2024


[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024


[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.

Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.09.006. 2024

  • Open Access.

12-Month Effectiveness and Tolerability of Brivaracetam in the Real-World: The International EXPERIENCE Pooled Analysis

Villanueva, Vicente; (...); Steinhoff, Bernhard J.

Meeting Abstract. 10.1212/WNL.0000000000201896. 2023


2019 SEFH National Survey: service portfolio, care activities, education and research in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11611. 2021


A brain atlas of axonal and synaptic delays based on modelling of cortico-cortical evoked potentials

Lemarechal, Jean-Didier; (...); David, Olivier

Article. 10.1093/brain/awab362. 2022


A EUROPEAN AUDIT OF REAL-WORLD USE OF ESLICARBAZEPINE ACETATE AS A TREATMENT FOR PARTIAL-ONSET SEIZURES: THE EURO-ESLI STUDY

Villanueva, V; (...); McMurray, R

Meeting Abstract. 2017


A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Zozaya, Neboa; (...); Hidalgo-Vega, Alvaro

Article. 10.33393/grhta.2022.2333. 2022


A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases.

Zozaya, Neboa; (...); Verde, Luis

Article. 10.1017/S0266462322000459. 2022


A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.

de Andrés-Nogales F; (...); Martínez-Olmos J

Article. 10.1007/s41669-020-00201-2. 2020


A MULTI-STAKEHOLDER MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD STUDY.

Casado, MA; (...); Grp MULTIDEX-EMD

Meeting Abstract. 10.1016/j.jval.2018.09.2545. 2018


A new definition and refocus of pharmaceutical care: the Barbate Document

Morillo-Verdugo R; (...); Poveda-Andrés JL

Article. 10.7399/fh.11389. 2020


A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).

Hahn, Cecil D.; (...); Dlugos, Dennis

Article. 10.1111/epi.17367. 2022


A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report

Auvin, S; (...); Villanueva, V

Article. 10.1186/s13023-019-1072-y. 2019


A survey of the European Reference Network EpiCARE on clinical practice for selected rare epilepsies.

Baumgartner T; (...); Sadowski K

Article. 10.1002/epi4.12459. 2021


A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Article. 10.1038/tpj.2015.80. 2016


A systematic review of behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate in real-world studies

Steinhoff, Bernhard J.; (...); Villanueva, Vicente

Meeting Abstract. 2021


Academic and employment insertion as a factor related to quality of life in patients with drug-resistant temporal lobe epilepsy.

Catalán-Aguilar J; (...); Cano-López I

Article. 10.33588/rn.7407.2020684. 2022


Accelerated long-term forgetting in resected and seizure-free temporal lobe epilepsy patients.

Visser M; (...); Avila C

Article. 10.1016/j.cortex.2018.02.017. 2019


Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.

Ballesta-López O; (...); Poveda-Andrés JL

Article. 10.1177/1078155220915953. 2020


Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety

Lagae L; (...); Yang H

Article. 10.1111/epi.13417. 2016


Aflibercept in exudative age related macular degeneration refractory to ranibizumab.

Ruiz Ramos J; (...); Gallego-Pinazo R

Article. 10.1016/j.oftal.2015.07.018. 2015


Age at surgery as a predictor of cognitive improvements in patients with drug-resistant temporal epilepsy

Cano-Lopez, I; (...); Villanueva, V

Article. 10.1016/j.yebeh.2017.03.002. 2017


Analisis de las causas de suspension de tratamiento con triple terapia antiviral en pacientes con hepatitis C.

Ruiz Ramos J; (...); Poveda Andrés JL

Abstract of Published Item. 10.7399/fh.2014.38.3.1171. 2014


Analysing criteria for price and reimbursement of orphan drugs in Spain.

Badia, X; (...); Tort, M

Article. 10.7399/fh.11147. 2019


Analysis of chemical contamination by hazardous drugs with BD HD Check(R) system in a tertiary hospital

Valero García S; (...); Poveda Andrés JL

Article. 10.1177/10781552211038518. 2021


Anidulafungin-Induced Alopecia

Ruiz-Ramos J; (...); Poveda-Andrés JL

Article. 10.1177/1060028014524534. 2014


Antiepileptic drug reduction and increased risk of stimulation-evoked focal to bilateral tonic-clonic seizure during cortical stimulation in patients with focal epilepsy

Hampel, Kevin G.; (...); Villanueva, Vicente

Article. 10.1016/j.yebeh.2017.12.033. 2018


Anti-GAD65-related epilepsy and its clinical spectrum

Marin Gracia, M.; (...); Villanueva, V.

Meeting Abstract. 2024


Antimicrobial stewardship programme implementation in a medical ward

Ruiz, J; (...); Poveda, JL

Article. 2018


Antimicrobial stewardship programme in critical care medicine: A prospective interventional study

Ruiz, J; (...); Catellanos, A

Article. 10.1016/j.medin.2017.07.002. 2018


Apuntes en Neurologia: una sintesis de la evidencia en trastornos neurologicos comunes paroxisticos y en trastornos neurodegenerativos.

Toledo M; (...); Villanueva V

Abstract of Published Item. 2018


Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).

Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ

Letter. 10.1111/jdv.19432. 2023


Assessment of the in vivo formation of biofilm on external ventricular drainages.

Ramírez P; (...); Bonastre J

Article. 10.1007/s10096-013-1895-8. 2013


Assessment of the Long-Term Efficacy and Safety of Adjunctive Perampanel in Adolescent Patients: Post Hoc Analysis of Open-Label Extension (OLEX) Studies

Pina-Garza, JE; (...); Laurenza, A

Meeting Abstract. 2018


Assessment of the quality of sample labelling for clinical research.

Pérez-Huertas P; (...); Poveda-Andrés JL

Article. 10.7399/fh.2016.40.2.9753. 2016


Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation

Sánchez-Lázaro I; (...); Aliño SF

Article. 10.2217/pgs.15.39. 2015


Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.

Iglesias Gómez R; (...); Poveda Andrés JL

Article. 10.1136/ejhpharm-2021-002741. 2021


Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018


Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2018.12.027. 2019


Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.

Steinhoff, Bernhard J; (...); Villanueva, Vicente

Review. 10.1016/j.yebeh.2021.107939. 2021


Behavioral disorder in people with an intellectual disability and epilepsy: A report of the Intellectual Disability Task Force of the Neuropsychiatric Commission of ILAE.

Kerr M; (...); Wilson S

Article. 10.1002/epi4.12018. 2016


Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022


Biosimilares: viejas polemicas con nuevos argumentos.

Poveda-Andrés JL, Bosó-Ribelles V

Editorial Material. 10.7399/fh.2015.39.3.8978. 2015


BK Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation in the Pediatric Population

Perez-Huertas, P; (...); Poveda-Andres, JL

Article. 10.1177/1043454216631952. 2017


Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience

Garcia-Robles, AA; (...); Fernandez-Navarro, JM

Meeting Abstract. 2017


BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice

Villanueva, V; (...); BRIVA-LIFE Study Grp

Article. 10.1111/ane.13059. 2019


BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice

Villanueva, V.; (...); Sansa, G.

Meeting Abstract. 2024


BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice.

Villanueva V; (...); Serratosa JM

Article. 10.1002/epi4.13078. 2024


Brivaracetam effectiveness and tolerability in older and younger adults with epilepsy: EXPERIENCE, a pooled analysis of international data from retrospective studies.

Faught, Edward; (...); Villanueva, Vicente

Article. 10.1016/j.yebeh.2024.109922. 2024


Calidad y Legibilidad de la Hoja de Informacion al Paciente en Estudios con Analisis Farmacogenetico.

Ruiz Ramos J; (...); Poveda Andrés JL

Article. 2015


Candidate Selection for Implantation: Noninvasive Predictors of Seizure Onset Zone Focality and Surgical Outcome in People with Drug-Resistant Epilepsy Evaluated by Intracranial Video-EEG Monitoring-A Retrospective Cohort Study

Jannone-Pedro, Nicolas; (...); Villanueva, Vicente

Article. 10.1155/2023/3455061. 2023


Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain

Garcia-Penas, JJ; (...); Villanueva-Haba, V

Article. 10.33588/rn.73S01.2021250. 2021


Cardiovascular response to stress in patients with drug-resistant epilepsy: preliminary data

Lozano-Garcia, A; (...); Cano-Lopez, I

Article. 10.6018/analesps.483021. 2021


CD4/CD8 ratio in aqueous humor in Uveitis.

Sanz-Marco E; (...); Diaz-Llopis M

Letter. 10.3109/09273948.2013.801993. 2013


Cenobamate in real-life setting: Final outcomes of an expanded access program

Villanueva-Haba, V.; (...); Massot-Tarrus, A.

Meeting Abstract. 2023


CLINICAL AND ECONOMIC CONSEQUENCES OF EPILEPSY TREATMENT ACROSS INCREMENTAL TREATMENT LINES IN SPAIN: A REAL LIFE DATABASE ANALYSIS

Toledano, R.; (...); Hernandez, I

Meeting Abstract. 2023


Clinical and economic implications of epilepsy management across treatment lines in Spain: a real-life database analysis.

Toledano R; (...); Pérez-Domper P

Article. 10.1007/s00415-023-11958-x. 2023


Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Megias-Vericat, JE; (...); Poveda, JL

Article. 10.1016/j.thromres.2021.07.009. 2021


Clinical characteristics of patients achieving seizure freedom in a phase 2 trial evaluating adjunctive cenobamate

Brandt, C.; (...); Steinhoff, B.

Meeting Abstract. 2022


Clinical evaluation of rituximab treatment for neuromyelitis optica

Fernández-Megía MJ; (...); Poveda-Andrés JL

Article. 10.1016/j.nrl.2014.09.001. 2015


Clinical experiences with cannabinoids in spasticity management in multiple sclerosis

Lorente Fernández L; (...); Casanova-Estruch B

Article. 10.1016/j.nrl.2013.06.014. 2014


Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model

Nogueras, A; (...); Calleja, MA

Letter. 10.1136/ejhpharm-2019-001905. 2019


Clinical Predictors of 12-Month Retention in Patients Treated with Eslicarbazepine Acetate: Real-World Evidence from the Euro-Esli Study

Sales, F; (...); Villanueva, V

Meeting Abstract. 2020


Clinical utility of Epitrack for differentiating profiles and patterns of post-surgical change in memory and quality of life in patients with drug-resistant epilepsy.

Lozano-García A; (...); González-Bono E

Article. 10.1080/23279095.2022.2036990. 2022


Cognitive phenotypes in patients with drug-resistant temporal lobe epilepsy: Relationships with cortisol and affectivity.

Cano-Lopez, Irene; (...); Gonzalez-Bono, Esperanza

Article. 10.1080/13854046.2024.2375605. 2024


Collaborative model of home delivery program in haemophilia through an association of patients

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018


Combination of Corpus Callosotomy and Vagus Nerve Stimulation in the Treatment of Refractory Epilepsy

Guillamon, E; (...); Villanueva, V

Article. 10.1159/000353979. 2014


Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo

Megias-Vericat, JE; (...); Poveda, JL

Meeting Abstract. 2020


Complementary and alternative medicine in epilepsy: A global survey of physicians' opinions.

Asadi-Pooya AA; (...); Jusupova A

Article. 10.1016/j.yebeh.2021.107835. 2021


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023


Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023


Cortisol and trait anxiety as relevant factors involved in memory performance in people with drug-resistant epilepsy

Cano-Lopez, I; (...); Villanueva, V

Article. 10.1016/j.yebeh.2018.12.022. 2019


COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

  • Open Access.

COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN

Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.

Meeting Abstract. 2024


Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1080/13696998.2017.1311903. 2017


Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.

Poveda JL; (...); Torres C

Article. 10.1080/14737167.2019.1635014. 2020


COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

Trillo, JL; (...); Torres, C

Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018


Cost-effectiveness of methoxy polyethylene glycolepoetin beta versus conventional epoetin in the treatment of anaemia secondary to chronic kidney disease in clinical practice

Lorente-Fernandez, L; (...); Poveda-Andres, JL

Article. 10.1136/ejhpharm-2013-000426. 2015


COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN

Bonanad, S; (...); Gonzalez-Dominguez, A

Meeting Abstract. 2020


Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021


Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis

Megias-Vericat, JE; (...); Poveda, JL

Letter. 10.1111/hae.13733. 2019


Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019


Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.

Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL

Editorial Material. 10.1016/j.farma.2024.08.001. 2024


Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.1080/17512433.2019.1573668. 2019


Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project

Blade, J; (...); Lizan, L

Article. 10.1136/bmjopen-2017-018850. 2018


Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021


Design of two parallel randomized, double-blind, placebo-controlled phase 3 studies to evaluate the safety and efficacy of XEN1101 as adjunctive therapy in the treatment of focal onset epilepsy

Perucca, E.; (...); Beatch, G. N.

Meeting Abstract. 2023


Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.

Angel Calleja, Miguel; (...); Gil, Alicia

Article. 10.1080/14737167.2022.2107507. 2022


Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Alvarez-Roman, MT; (...); Badia, X

Article. 10.1177/2284240319880534. 2019


DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alvarez, E.; (...); Badia, F. J.

Meeting Abstract. 2019


Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024


Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024


DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019


Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019


Development and validation of the Epilepsy Perceived Stress Inventory for Adults (EPSI-A): A pilot study

Catalan-Aguilar, Judit; (...); Gonzalez-Bono, Esperanza

Article. 10.1016/j.yebeh.2024.110142. 2024


Diagnostic challenges in epilepsy

Hampel, KG; (...); Villanueva, V

Article. 10.33588/rn.6806.2018242. 2019


Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?

Lawthom, C; (...); Villanueva, V

Editorial Material. 10.1007/s40120-018-0111-2. 2018


Dose banding aplicado a la elaboracion de antineoplasicos: una revision narrativa de la literatura.

Pérez Huertas P; (...); Poveda Andrés JL

Article. 10.7399/fh.2015.39.4.8839. 2015


Drug Interaction Between Oral Cyclosporine Modified and Iron

Domingo-Chiva, E; (...); Poveda-Andres, JL

Article. 10.1177/1060028013514734. 2014


Drug load and memory during intracarotid amobarbital procedure in epilepsy

Lozano-García A; (...); Villanueva V

Editorial Material. 10.1111/ane.13491. 2021


Drug-resistant epilepsy: Definition and treatment alternatives

Gonzalez, FJL; (...); Cerda, JMM

Review. 10.1016/j.nrl.2014.04.012. 2015


Early Add-on Lacosamide in a Real-Life Setting: Results of the REALLY Study

Villanueva, V; (...); Saiz-Diaz, RA

Article. 10.1007/s40261-014-0255-5. 2015


Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases

Megias-Vericat, JE; (...); Poveda, JL

Review. 10.1007/s10072-017-2833-9. 2017


EARLY-ESLI study: Long-term experience with eslicarbazepine acetate after first monotherapy failure

Villanueva, V; (...); Bonet, M

Article. 10.1111/ane.12720. 2017


ECONOMIC IMPACT LINKED TO THE REDUCTION OF EXACERBATIONS WHEN A TREATMENT REGIME WITH INHALED ANTIBIOTICS IS SWITCHED TO AZTREONAM LYSINE IN PATIENTS WITH CYSTIC FIBROSIS AND CHRONIC PULMONARY INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA

Sole A; (...); Casado MA

Meeting Abstract. 10.1016/j.jval.2014.08.1659. 2014


Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

Ribera, E; (...); Hernandez-Novoa, B

Article. 10.1016/j.eimc.2016.11.015. 2018


Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.

Torres Martínez E; (...); Vento M

Article. 10.1016/j.anpedi.2020.03.009. 2020


Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome

Devinsky, O; (...); GWPCARE3 Study Grp

Article. 10.1056/NEJMoa1714631. 2018


Effect of concomitant medications on adverse event frequency, severity, and resolution in a cenobamate open-label trial

Steinhoff, B.; (...); Villanueva, V.

Meeting Abstract. 2024


EFFECT OF CYP3A5 GENOTYPE ON TACROLIMUS DOSE REQUIREMENT, NEPHROTOXICITY AND ACUTE REJECTION IN KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES

Rojas, L.; (...); Alino, S. F.

Article. 2013


Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies

Rojas L; (...); Aliño SF

Article. 10.1038/tpj.2014.38. 2015


EFFECTIVENESS AND SAFETY OF ESLICARBAZEPINE ACETATE FOR TREATMENT OF PARTIAL-ONSET SEIZURES IN CLINICAL PRACTICE ACCORDING TO AGE DECADE OF PATIENTS

Rocamora, R; (...); Villanueva, V

Meeting Abstract. 2017


Effectiveness and safety of perampanel in elderly epilepsy patients (aged >= 65 years) treated in everyday clinical practice

McMurray, Rob; (...); Villanueva, Vicente

Meeting Abstract. 2021


Effectiveness and Safety/Tolerability of Eslicarbazepine Acetate in Epilepsy Patients Aged = 60 Versus 60Years: A Subanalysis from the Euro-Esli Study.

Lawthom, C; (...); Villanueva, V

Article. 10.1007/s40120-019-0137-0. 2019


Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records.

Villanueva V; (...); Steinhoff BJ

Article. 10.1007/s40263-023-01033-4. 2023


Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis.

Szaflarski, Jerzy P; (...); Villanueva, Vicente

Article. 10.1007/s00415-024-12253-z. 2024


Effectiveness and Tolerability of Perampanel in Epilepsy Patients Treated in Routine Clinical Practice: a Global Pooled Analysis Study

D'Souza, Wendyl; (...); Villanueva, Vicente

Meeting Abstract. 2021


Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021


Effectiveness, safety and tolerability of perampanel by age group when used to treat people with focal and generalized epilepsy in clinical practice: The PERMIT Extension study.

Wheless J; (...); Villanueva V

Article. 10.1016/j.yebeh.2023.109369. 2023


Effectiveness, safety and tolerability of perampanel in adolescents with focal and generalised seizures: evidence from clinical practice

Gil, Francisco; (...); Villanueva, Vicente

Meeting Abstract. 2021


EFFECTS OF POLYMORPHIMS OF CYP3A5 AND ABCB1 GENES ON CHRONIC NEPHROPATHY: COHORT STUDY

Rojas, L.; (...); Alino, S. F.

Article. 2013


Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.

Piña-Garza JE; (...); Malhotra M

Article. 10.1016/j.yebeh.2019.106876. 2020


Efficacy and safety of cenobamate as adjunctive therapy in patients with uncontrolled focal seizures: results from two double-blind, placebo-controlled, international studies

Steinhoff, BJ; (...); Brandt, C

Meeting Abstract. 2020


Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series

Gomez-Ibanez, A; (...); Villanueva, V

Article. 10.1016/j.seizure.2017.04.003. 2017


Efficacy and safety of stiripentol in the prevention and cessation of status epilepticus: A systematic review.

Specchio N; (...); Trinka E

Article. 10.1002/epi4.13036. 2024


Efficacy of add-on Cenobamate treatment in refractory epilepsy due to Rasmussen's encephalitis.

Schulze-Bonhage A; (...); Villanueva V

Article. 10.1002/epi4.13060. 2024


Efficacy of perampanel in a patient with epilepsia partialis continua.

Argente-Escrig, H, Gomez-Ibanez, A, Villanueva, V

Article. 10.1016/j.ebcr.2017.09.004. 2017


Efficacy of stiripentol in the management of status epilepticus: A systematic review

Auvin, S.; (...); Trinka, E.

Meeting Abstract. 2024


Efficacy, Safety and Tolerability of Soticlestat (TAK-935/OV935) as Adjunctive Therapy in Pediatric Patients with Dravet Syndrome and Lennox-Gastaut Syndrome (ELEKTRA)

Hahn, Cecil D.; (...); Dlugos, Dennis

Meeting Abstract. 2021


eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Megias-Vericat, JE

Meeting Abstract. 2018


EPICON consensus: recommendations for proper management of switching to eslicarbazepine acetate in epilepsy

Villanueva, V; (...); Viteri, C

Article. 10.1016/j.nrl.2016.04.014. 2018


Epilepsy surgery beyond 50?years: Long-term seizure and cognitive outcomes.

Gómez-Ibáñez A; (...); Villanueva-Haba V

Article. 10.1016/j.jns.2020.116872. 2020


Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies

Carreño M; (...); Graus, F

Article. 10.1016/j.eplepsyres.2016.12.010. 2017


ESLICARBAZEPINE ACETATE AS A TREATMENT FOR PARTIAL-ONSET SEIZURES IN PATIENTS WITH PSYCHIATRIC COMORBIDITIES, INCLUDING DEPRESSION

Assenza, G; (...); Villanueva, V

Meeting Abstract. 2017


Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-Esli

Holtkamp, M; (...); Villanueva, V

Article. 10.1111/ane.13023. 2019


Eslicarbazepine acetate in epilepsy patients with psychiatric comorbidities and intellectual disability: Clinical practice findings from the Euro-Esli study

Doherty, CP; (...); Villanueva, V

Article. 10.1016/j.jns.2019.04.040. 2019


Eslicarbazepine Acetate in Post-Stroke Epilepsy: A post-hoc Analysis from the Clinical Practice Study Euro-Esli

Sales, F; (...); Fernandes, H

Meeting Abstract. 2019


Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli.

Sales F; (...); Villanueva V

Article. 10.1111/ane.13323. 2020


Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies

Shorvon, SD; (...); Ben-Menachem, E

Review. 10.1007/s00415-016-8338-2. 2017


Estudio de utilizacion de boceprevir y telaprevir para el tratamiento de la hepatitis C cronica.

Marrero-Álvarez P; (...); Poveda-Andrés JL

Abstract of Published Item. 10.7399/FH.2014.38.1.1128. 2014


Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures

Villanueva, Vicente; (...); Santagueda, Patricia

Article. 10.1007/s00415-017-8618-5. 2017


EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

Badia, F. J.; (...); Shepherd, J.

Meeting Abstract. 2019


Evidence for degraded low frequency verbal concepts in left resected temporal lobe epilepsy patients

Visser, M; (...); Avila, C

Article. 10.1016/j.neuropsychologia.2018.04.020. 2018


Experience in the management of immunosuppressant treatment with hepatitis C virus protease inhibitors

Ruiz Ramos J; (...); Poveda Andrés JL

Article. 10.1016/j.gastrohep.2014.05.004. 2014


Experience of Home Delivery Program in Haemophilia Through an Association of Patients

Megias Vericat, J. E.; (...); Bonanad Boix, S.

Meeting Abstract. 2017


EXPERTS CONSENSUS ON THE FUTURE OF RARE DISEASES CARE AND ORPHAN DRUGS ACCESS IN SPAIN: A DELPHI STUDY

Paz S; (...); Urcelay J

Meeting Abstract. 10.1016/j.jval.2015.09.2016. 2015


Exploratory analysis for the implementation of antineoplastic logarithmic dose banding

Albert-Mari, A; (...); Poveda-Andres, JL

Article. 10.1007/s11096-018-0714-9. 2018


EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY

F, de Andres-Nogales; (...); Martinez, M.

Meeting Abstract. 2019


Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study

Garces, M; (...); Olmedilla, N

Article. 10.1016/j.yebeh.2014.05.015. 2014


Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease

Beltran, B; (...); Nos, P

Article. 10.1159/000492626. 2019


Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021


General Study: 1-Year Real-Life Effectiveness and Tolerability of Perampanel in Idiopathic Generalized Epilepsy

Villanueva, V; (...); Tortosa, D

Meeting Abstract. 2018


Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J; (...); Moret-Tatay I

Article. 10.3390/ijms25073717. 2024


Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population

Bosó V; (...); Aliño SF

Article. 10.1097/FTD.0b013e3182a94e65. 2014


Global pooled analysis of perampanel in epilepsy patients treated in routine clinical practice: the PERMIT study

Villanueva, Vicente; (...); Trinka, Eugen

Meeting Abstract. 2021


Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe.

Cardenal-Muñoz E; (...); Aibar JÁ

Article. 10.1002/epi4.12569. 2022


Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022


Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12568. 2017


Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML

Kwon M; (...); Diez-Martin JL

Article. 10.1038/bmt.2017.36. 2017


Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study

Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units

Article. 10.7399/fh.10935. 2018


Hazardous drugs: new challenges, new opportunities.

Valero García S; (...); Poveda Andrés JL

Article. 10.7399/fh.2016.40.2.10462. 2016


Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022


High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022


Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022


Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021


How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022


Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).

Villanueva V; (...); Subías-Labazuy S

Article. 10.1016/j.yebeh.2021.108222. 2021


Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2016.1231405. 2017


Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart (R) in patients with multiple sclerosis

Edo Solsona MD; (...); Poveda Andrés JL

Article. 10.2147/PPA.S127508. 2017


IMPACT OF ADHERENCE ON SUBCUTANEOUS INTERFERON BETA-1A EFFECTIVENESS ADMINISTERED BY REBISMART (R) IN PATIENTS WITH MULTIPLE SCLEROSIS

Edo-Solsona, M.; (...); Poveda-Andres, J.

Meeting Abstract. 10.1016/j.jval.2016.09.512. 2016

  • Open Access.

Impact of an antimicrobial stewardship program on critical haematological patients.

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.7399/fh.2017.41.4.10709. 2017


Impact of antiseizure medication with a very long half-life on long term video-EEG monitoring in focal epilepsy.

Hampel, Kevin G.; (...); Villanueva, Vicente

Article. 10.1016/j.seizure.2023.12.010. 2023


Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1080/10428194.2020.1839650. 2020


Impact of COVID-19 on Spanish patients with Dravet syndrome and their caregivers: consequences of lockdown

Munoz, EC; (...); Aibar JA

Article. 10.33588/rn.7302.2021006. 2021


IMPACT OF INTELLECTUAL DISABILITY ON THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE AS A TREATMENT FOR PARTIAL-ONSET SEIZURES

Bagary, M; (...); Villanueva, V

Meeting Abstract. 2017


Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1038/tpj.2017.19. 2018


Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1097/FPC.0000000000000286. 2017


Impact of Polytherapy on Memory Functioning in Patients With Drug-Resistant Epilepsy: The Role of Attention and Executive Functions.

Lozano-Garcia, Alejandro; (...); Gonzalez-Bono, Esperanza

Article. 10.1093/arclin/acad086. 2023


Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation

Ruiz J; (...); Aliño SF

Article. 10.3390/ijms160920168. 2015


Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Badia X; (...); Hernández C

Article. 10.1186/s13023-020-01507-4. 2020


Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Meeting Abstract. 2015


IMPACT OF TREATMENT REFRACTORINESS ON THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE IN CLINICAL PRACTICE

Holtkamp, M; (...); Villanueva, V

Meeting Abstract. 2017


Impact of voriconazole plasma concentrations on treatment response in critically ill patients

Ruiz, J; (...); Ramirez, P

Article. 10.1111/jcpt.12817. 2019


Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases

Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL

Article. 10.7399/fh.11262. 2020


Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1159/000478969. 2018


Incompatibility of undiluted busulfan injection with a needle-free valve

Cueto-Sola, M; (...); Poveda-Andres, JL

Letter. 10.2146/ajhp140111. 2014


Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Vericat, JEM; (...); Bonanad, S

Meeting Abstract. 2018


Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

Megias-Vericat, Juan Eduardo; (...); Bonanad, Santiago

Meeting Abstract. 10.1182/blood.V128.22.3802.3802. 2016


Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies

Megías-Vericat JE; (...); Aliño SF

Review. 10.1038/tpj.2014.80. 2015


Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

Bastida, G; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019


Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017


Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.

Ruiz J; (...); Poveda JL

Article. 10.23736/S0026-4946.18.04978-2. 2018


Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Megías-Vericat JE; (...); Montesinos P

Article. 10.1097/FPC.0000000000000431. 2021


Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Meeting Abstract. 2015


Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies.

Fernandez-Anaya, Silvia; (...); Sarasa, Pilar

Article. 10.1080/00207454.2021.1925667. 2021


Initiating antiepilepsy treatment: An update of expert consensus in Spain.

Villanueva V; (...); Gil-Nagel A

Article. 10.1016/j.yebeh.2020.107540. 2021


Interdisciplinary recommendations document to improve adherence in patients with chronic inflammatory diseases: Adhing recommendations.

Bermejo San José F; (...); Sanromán-Álvarez L

Article. 10.7399/fh.2016.40.5.10180. 2016


Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12842. 2019


Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.

Solana-Altabella A; (...); Poveda JL

Article. 10.1177/1078155220904410. 2020


Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP

Article. 10.1136/ejhpharm-2020-002322. 2020


Involvement of mental health professionals in the treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND): results of a multinational European electronic survey

Waltereit, R; (...); Auvin, S

Article. 10.1186/s13023-021-01800-w. 2021


Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024


Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula

Article. 10.3390/antibiotics13080706. 2024


La reserva cognitiva como factor modulador del impacto de la cirugía sobre la memoria visual y la denominación en pacientes con epilepsia del lóbulo temporal.

Cano-Lopez, I; (...); Gonzalez-Bono, E

Article. 10.33588/rn.7308.2021109. 2021


Lacosamide monotherapy in clinical practice: A retrospective chart review

Villanueva, V; (...); Serratosa, J

Review. 10.1111/ane.12920. 2018


Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures

Pina-Garza, JE; (...); Meador, KJ

Article. 10.1016/j.yebeh.2018.03.029. 2018


Long-Term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures.

Klein, Pavel; (...); Villanueva, Vicente

Article. 10.1212/WNL.0000000000200792. 2022


Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study

Villanueva, V; (...); Molins, A

Article. 10.1016/j.eplepsyres.2014.04.014. 2014


Long-Term Soticlestat Treatment in Patients with Developmental and/or Epileptic Encephalopathies in the ENDYMION Ongoing Open-Label Extension Study

Hahn, Cecil D.; (...); Dlugos, Dennis

Meeting Abstract. 2021


Long-term, quality of life in epilepsy inventory-31 (QOLIE-31) improvements in adults with focal onset seizures treated with XEN1101 in an ongoing, open-

Brandt, C.; (...); Beatch, G. N.

Meeting Abstract. 2024


Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

  • Open Access.

Management of patients with Dravet syndrome in real-world clinical practice across five countries in Europe: Impact of treatment-related burden on health outcomes

Ross, E.; (...); Andrews, J. S.

Meeting Abstract. 2024


Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022


Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021


Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.

Rojas LE; (...); Aliño SF

Article. 10.1097/FPC.0b013e3283642fb3. 2013


Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022


Metyrapone as treatment in the neonatal McCune-Albright syndrome

de Mingo, Carmen; (...); Garcia-Robles, Ana

Article. 10.1515/jpem-2020-0036. 2020


Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021


Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021


Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.

Fernandez-Megia, MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.10793. 2018


MONOZEB: Long-term observational study of eslicarbazepine acetate monotherapy

Villanueva, V; (...); Hampel, K

Article. 10.1016/j.yebeh.2019.05.003. 2019


Multichannel dynamic modeling of non-Gaussian mixtures

Safont, G; (...); Villanueva, V

Article. 10.1016/j.patcog.2019.04.022. 2019


Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021


N. VICTOR JIMENEZ TORRES (1942-2015) IN MEMORIAM

Climente Martí M, Poveda Andrés JL, Culebras J

Biographical-Item. 10.3305/nh.2015.32.4.9704. 2015


National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021


National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022


NEOPLASM study: Real-life use of lacosamide in patients with brain tumor-related epilepsy

Villanueva, V; (...); Gago, A

Article. 10.1016/j.yebeh.2016.09.033. 2016


New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024


New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.

Villanueva V; (...); López-González FJ

Review. 10.33588/rn.72S01.2021017. 2021


Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain.

Villanueva, Vicente; (...); Gil, Alicia

Article. 10.1016/j.yebeh.2022.109054. 2023


Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022


ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023


Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023


Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Poveda, JL

Meeting Abstract. 2018


OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024


Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Garcia-Robles, Ana; (...); Carrascosa, MA

Article. 10.3389/fped.2020.00372. 2020


Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021


Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

  • Open Access.

Patient profile, management, and quality of life associated with Dravet syndrome: a cross-sectional, multicentre study of 80 patients in Spain.

Gil-Nagel, Antonio, Sanchez-Carpintero, Rocio, Villanueva, Vicente

Article. 10.1038/s41598-023-30273-z. 2023


Perampanel as Early Add on Therapy for Epilepsy Patients with Focal -Onset an Generalized-Onset Seizures Treated in Clinical Practice(p1-1.Virtua)

Santamarina, Estevo; (...); Villanueva, Vicente

Meeting Abstract. 2022


Perampanel as Early Add on Therapy for Epilepsy Patients with Focal -Onset and Generalized-Onset Seizures Treated in Clinical Practice(p1-1.Virtual)

Santamarina, Estevo; (...); Villanueva, Vicente

Meeting Abstract. 2022


Perampanel as early add-on therapy for epilepsy patients with focal and generalised seizures treated in clinical practice

Santamarina Perez, Estevo; (...); Villanueva, Vicente

Meeting Abstract. 2021


Perampanel as Early Add-on Therapy for Epilepsy Patients with Focal and Generalized Seizures Treated in Clinical Practice

Santamarina, Estevo; (...); Villanueva, Vicente

Meeting Abstract. 2021


Perampanel for the treatment of Asian people with epilepsy: Real-world evidence from the PERMIT extension study.

Wu, Tony; (...); Villanueva, Vicente

Article. 10.1016/j.jns.2024.123173. 2024


Perampanel for the treatment of epilepsy with genetic aetiology: Real-world evidence from the PERMIT Extension study.

Delanty N; (...); Villanueva V

Article. 10.1016/j.eplepsyres.2024.107339. 2024


Perampanel for the treatment of focal and generalised seizures in patients with epilepsy with tumour aetiology: evidence from clinical practice

Coppola, Antonietta; (...); Villanueva, Vicente

Meeting Abstract. 2021


Perampanel for the treatment of patients with myoclonic seizures in clinical practice: Evidence from the PERMIT study

D'Souza, Wendyl; (...); Villanueva, Vicente

Article. 10.1016/j.seizure.2022.06.008. 2022


Perampanel for the Treatment of People with Idiopathic Generalized Epilepsy in Clinical Practice.

Trinka E; (...); Villanueva V

Article. 10.1111/epi.17631. 2023


Perampanel for treatment of epilepsy with tumour, vascular or traumatic brain injury aetiology: Evidence from the PERMIT extension study

Strzelczyk, A.; (...); Villanueva, V.

Meeting Abstract. 2024


Perampanel for treatment of focal and generalized epilepsy in everyday clinical practice: Evidence from permit extension

Trinka, Eugen; (...); Villanueva, Vicente

Meeting Abstract. 10.1016/j.jns.2023.121561. 2023


Perampanel for Treatment of People with a Range of Epilepsy Aetiologies in Clinical Practice: Evidence from the PERMIT Extension Study.

Strzelczyk, Adam; (...); Villanueva, Vicente

Article. 10.1007/s40120-024-00618-5. 2024


Perampanel in adult epilepsy patients treated in everyday clinical practice: results from an interim pooled analysis of real-world studies

Strzelczyk, Adam; (...); Villanueva, Vicente

Meeting Abstract. 2021


PERAMPANEL IN ROUTINE CLINICAL USE ACROSS EUROPE: POOLED OBSERVATIONAL STUDIES

Rohracher, A; (...); Trinka, E

Meeting Abstract. 2017


Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data.

Rohracher, A; (...); Trinka, E

Article. 10.1111/epi.14520. 2018


Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study

Villanueva, V; (...); Salas-Puig, J

Article. 10.1111/epi.14522. 2018


Perampanel Monotherapy for Focal and Generalized Epilepsy in Clinical Practice

Chinvarun, Yotin; (...); Villanueva, Vicente

Article. 10.1155/2023/2852853. 2023


Perampanel monotherapy in epilepsy patients with focal and generalised seizures: real-world experience

Alsaadi, Taoufik; (...); Villanueva, Vicente

Meeting Abstract. 2021


Perampanel outcomes at different stages of treatment in people with focal and generalized epilepsy treated in clinical practice: Evidence from the PERMIT study.

Liguori, Claudio; (...); Villanueva, Vicente

Article. 10.3389/fneur.2023.1120150. 2023


PERAMPANEL USE IN OLDER PEOPLE WITH EPILEPSY: POOLED DATA FROM EUROPEAN OBSERVATIONAL STUDIES

Neuray, C; (...); Trinka, E

Meeting Abstract. 2017


PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice

Villanueva, Vicente; (...); Trinka, Eugen

Article. 10.1007/s00415-021-10751-y. 2021


Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy

Margusino-Framiñán L; (...); Morillo-Verdugo R

Article. 10.7399/fh.11498. 2020


Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025


Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Montesinos, P

Review. 10.2174/1389200218666171101124931. 2018


Pharmacogenomics and the treatment of acute myeloid leukemia

Megías-Vericat JE; (...); Aliño SF

Review. 10.2217/pgs-2016-0055. 2016


Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with in adequately controlled partial-onset seizures

Villanueva, V; (...); Hussein, Z

Article. 10.1016/j.eplepsyres.2016.08.025. 2016


Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021


Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022


Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.

Calleja Hernández MÁ; (...); Aragon, B

Article. 10.7399/fh.2017.41.1.10463. 2017


Physical Activity In Haemophilia: Hemorrhagic Risk And Factor Levels (myPKFiT)

Querol-Fuentes, F; (...); Bonanad, S

Meeting Abstract. 2017


Pilot evaluation of home delivery programme in haemophilia

Megias-Vericat, JE; (...); Poveda-Andres, JL

Article. 10.1111/jcpt.12718. 2018


PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS

Vericat, JEM; (...); Iorio, A

Meeting Abstract. 2020


Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies

Elger, C; (...); Soares-da-Silva, P

Article. 10.1111/cns.12765. 2017


Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis

Megías-Vericat JE; (...); Aliño SF

Letter. 10.1038/tpj.2015.79. 2016


Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate - Expert opinion

Peltola, J; (...); Villanueva, V

Article. 10.1016/j.yebeh.2015.05.036. 2015


Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process

Valero, S; (...); Poveda, JL

Article. 10.1016/j.yrtph.2018.03.001. 2018


Predictors of seizure freedom, response and retention after 12 months of treatment with eslicarbazepine acetate: A post-hoc analysis of the Euro-Esli study

Sales, F; (...); Villanueva, V

Article. 10.1016/j.eplepsyres.2021.106653. 2021


PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS

Garcia, EG; (...); Ivorra, JAR

Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019


Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.

García-Robles A; (...); Aguar-Carrascosa M

Letter. 10.1016/j.anpedi.2020.06.008. 2021


Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021


Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

  • Open Access.

Presurgical Use of Cenobamate for Adult and Pediatric Patients Referred for Epilepsy Surgery: Expert Panel Recommendations.

Laxer KD; (...); Villanueva V

Article. 10.1007/s40120-024-00651-4. 2024


Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021


Probabilistic Distance for Mixtures of Independent Component Analyzers

Safont, G; (...); Villanueva, V

Article. 10.1109/TNNLS.2017.2663843. 2018


Probabilistic functional tractography of the human cortex revisited

Trebaul, L; (...); David, O

Article. 10.1016/j.neuroimage.2018.07.039. 2018


Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Article. 2014


Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy

Eduardo Megias, Juan; (...); Angel Sanz, Miguel

Article. 2014


PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS

Megias Vericat, J. E.; (...); Sanz, M. A.

Article. 2015

  • Open Access.

Prognostic value of the 5-SENSE Score to predict focality of the seizure-onset zone as assessed by stereoelectroencephalography: a prospective international multicentre validation study.

Astner-Rohracher, Alexandra; (...); Frauscher, Birgit

Article. 10.1136/bmjno-2024-000765. 2024


Proposed Recommendations for the Management of Depression in Adults with Epilepsy: An Expert Consensus.

Villanueva, Vicente; (...); Bobes, Julio

Article. 10.1007/s40120-023-00437-0. 2023


Prospective study of cenobamate on cognition, affectivity and quality of life in focal epilepsy.

Catalan-Aguilar, Judit; (...); Villanueva, Vicente

Article. 10.1002/epi4.12857. 2023


Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler

Megias-Vericat, JE; (...); Poveda, JL

Letter. 10.1097/DSS.0000000000001046. 2017


Psychiatric symptoms after temporal epilepsy surgery. A one-year follow-up study

Iranzo-Tatay, C; (...); Villanueva, V

Article. 10.1016/j.yebeh.2017.02.029. 2017


Quality of life in drug-resistant epilepsy: relationships with negative affectivity, memory, somatic symptoms and social support

Cano-Lopez, I; (...); Gonzalez-Bono, E

Article. 10.1016/j.jpsychores.2018.09.001. 2018


Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker

Perez-Alenda, S; (...); Querol, F

Letter. 10.1111/hae.13388. 2018


Real-life evidence about the use of intravenous brivaracetam in urgent seizures: The BRIV-IV study.

Villanueva V; (...); Escalza I

Article. 10.1016/j.yebeh.2023.109384. 2023


Real-Time Localization of Epileptogenic Foci EEG Signals: An FPGA-Based Implementation

Frances-Villora, JV; (...); Guerrero-Martinez, JF

Article. 10.3390/app10030827. 2020


Real-world clinical burden of non-seizure symptoms among patients with dravet syndrome or Lennox- Gastaut syndrome in Europe: Results from a global multinational survey

Berthoz, F. Truong; (...); Andrews, J. S.

Meeting Abstract. 2024


REAL-WORLD EFFECTIVENESS AND TOLERABILITY OF ESLICARBAZEPINE ACETATE IN PATIENTS RECEIVING VERSUS NOT RECEIVING OTHER SODIUM-CHANNEL BLOCKERS

Lawthom, C; (...); Villanueva, V

Meeting Abstract. 2017


Real-World Experience of Perampanel Monotherapy in Epilepsy Patients with Focal-Onset and Generalized-Onset Seizures

Alsaadi, Taoufik; (...); Villanueva, Vicente

Meeting Abstract. 2022


Real-world experience of treating patients aged <12 years with perampanel

Auvin, Stephane; (...); Villanueva, Vicente

Meeting Abstract. 2021


Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program.

Villanueva, Vicente; (...); Rodriguez-Uranga, Juan J.

Article. 10.1002/epi4.12757. 2023


Reduction in alert fatigue in an assisted electronic prescribing system, through the Lean Six Sigma methodology.

Cuéllar Monreal MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.2017.41.1.10434. 2017


Refractory status epilepticus due to vitamin B6 deficit in a Parkinson's disease patient in treatment with levodopa/carbidopa intestinal gel

Baviera-Munoz, R.; (...); Martinez-Torres, I.

Letter. 10.1016/j.nrl.2021.10.002. 2022


Refractory status epilepticus due to vitamin B6 deficit in a Parkinson's disease patient in treatment with levodopa/carbidopa intestinal gel.

Baviera-Muñoz R; (...); Martinez-Torres I

Article. 10.1016/j.nrleng.2021.10.002. 2022


Reply to letter to the editor: "The psychiatric risks of temporal epilepsy surgery. What should patients be told?"

Iranzo-Tatay, C; (...); Villanueva, V

Letter. 10.1016/j.yebeh.2017.09.004. 2018


Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.

Nabbout, Rima; (...); Cross, J. Helen

Article. 10.1016/j.seizure.2023.05.003. 2023


Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study

Villanueva, V; (...); Baiges, JJ

Article. 10.1016/j.eplepsyres.2016.08.001. 2016


Safety, efficacy and outcome-related factors of perampanel over 12months in a real-world setting: The FYDATA study (vol 126, pg 201 , 2016)

Villanueva, V; (...); Baigesr, JJ

Correction. 10.1016/Leplepsyres.2016.12.005. 2017


Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice.

Rocamora R; (...); Villanueva V

Article. 10.1016/j.seizure.2019.12.022. 2020


Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.

Sole, A; (...); Peman, J

Article. 10.1111/ajt.14580. 2018


SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11565. 2020


Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice

Aguas Peris M; (...); Nos, P

Article. 10.1097/MIB.0000000000001182. 2017


Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice

Aguas, M; (...); Nos, P

Meeting Abstract. 2017


Single Nucleotide Polymorphisms, SNPs, Associated With the Efficacy and Security of Immunosuppressive Treatment in Heart Transplantation

Sanchez-Lazaro, I.; (...); Salvador-Sanz, A.

Article. 10.1016/j.healun.2014.01.392. 2014


SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022


SNPs and taxane toxicity in breast cancer patients

Bosó V; (...); Aliño SF

Article. 10.2217/PGS.14.127. 2014


Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures.

Carreño M; (...); Villanueva V

Article. 10.1002/epi4.12936. 2024


Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

Cantón R; (...); Solé A

Article. 10.1016/j.arbres.2014.09.021. 2015


Stereoencephalography-guided thermocoagulation: Experience in our centre

De Castro Garcia, A. Celdran; (...); Villanueva, V.

Meeting Abstract. 2024


Stress phenotypes in epilepsy: impact on cognitive functioning and quality of life.

Catalán-Aguilar J; (...); Cano-López I

Article. 10.3389/fpsyg.2023.1100101. 2023


Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital

Pérez-Cebrián M; (...); Llopis-González A

Article. 2015


Sustained =90% response and seizure freedom in patients with focal-onset seizures treated with cenobamate

Alvarez-Baron, E., Thangavelu, K., Villanueva, V.

Meeting Abstract. 2023


Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Megías-Vericat JE; (...); Montesinos P

Review. 10.3390/pharmaceutics14040878. 2022


The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022


The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022


The Charlotte Project: Recommendations for patient-reported outcomes and clinical parameters in Dravet syndrome through a qualitative and Delphi consensus study.

Aledo-Serrano Á; (...); Sánchez-Carpintero R

Article. 10.3389/fneur.2022.975034. 2022


The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis

Kalilani, L; (...); Villanueva, V

Review. 10.1111/epi.14596. 2018


The number of anti-seizure medications mediates the relationship between cognitive performance and quality of life in temporal lobe epilepsy.

Lozano-García A; (...); Cano-López I

Article. 10.1016/j.yebeh.2020.107699. 2021


The relationship between memory and quality of life is mediated by trait anxiety in patients with temporal lobe epilepsy.

Cano-Lopez, Irene; (...); Gonzalez-Bono, Esperanza

Article. 10.1007/s11136-022-03306-9. 2022


The significance of very long half-life in the context of antiseizure medication withdrawal during long-term video-EEG monitoring.

Hampel, Kevin Gil; (...); Villanueva, Vicente

Letter. 10.1016/j.seizure.2024.01.006. 2024


The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024


The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus

Torrent-Farnell, J; (...); Lizan, L

Article. 10.1016/j.healthpol.2018.03.002. 2018


Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations

Steinhoff, Bernhard J.; (...); Villanueva, Vicente

Review. 10.1177/17562864241256733. 2024


Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials

Privitera, M; (...); VanLandingham, K

Article. 10.1111/epi.16878. 2021


Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials

Cohen, JM; (...); Zuberi, SM

Article. 10.1111/epi.16974. 2021


Time to Onset of Efficacy of Cannabidiol (CBD) During Titration in Patients with Lennox-Gastaut Syndrome and Dravet Syndrome Enrolled in Three Randomized Controlled Trials

Mazurkiewicz-Beldzinska, M; (...); Knappertz, V

Meeting Abstract. 2019


Time To Onset Of Efficacy Of Cannabidiol (CBD) During Titration In Patients With Lennox-Gastaut Syndrome Or Dravet Syndrome Enrolled In Three Randomised Controlled Trials

Mazurkiewicz-Beldzinska, M; (...); Knappertz, V

Meeting Abstract. 2019


Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

Marques MR; (...); Mangas-Sanjuan V

Article. 10.1111/apa.14944. 2020


Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy

Del Rio-Bermudez, C; (...); Poveda, JL

Editorial Material. 10.1186/s40545-020-00276-6. 2020


Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024


Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.

Megías Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.rx.2015.01.008. 2015


Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature

Lizan, L; (...); Polanco, C

Review. 10.2147/PPA.S67253. 2014


Treatment patterns and disease burden among patients with Lennox- Gastaut syndrome in Europe: A real-world survey

Benitez, A.; (...); Andrews, J. S.

Meeting Abstract. 2024


Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?

Bejar, S; (...); Mateu, PN

Meeting Abstract. 2020


Use and handling safety of Mini-Spike 2 (R) chemo and puresite for safe chemotherapy compounding in a hospital pharmacy

Garcia, SV; (...); Andres, JLP

Article. 10.1016/j.yrtph.2018.10.002. 2018


Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients

García-Robles AA; (...); Poveda JL

Letter. 10.1016/j.jns.2016.04.048. 2016


USE OF CAPLACIZUMAB IN THE ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

Dominguez Hernandez, L.; (...); Gomez Segui, I

Meeting Abstract. 2019

  • Open Access.

Use of Stiripentol in Patients with Dravet Syndrome: Common Practice Among Experts in Spain.

Garcia-Penas, Juan Jose; (...); Sanchez-Carpintero, Rocio

Article. 10.1007/s40120-024-00677-8. 2024


VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA

Poveda, J. L.; (...); Lizan, L.

Meeting Abstract. 2023


What do 90-99% responder rates mean in patients treated with cenobamate: results from an open label extension study

Serratosa, J.; (...); Villanueva, V.

Meeting Abstract. 2023


What do 90-99% responder rates mean in patients treated with cenobamate: results from the open label extension (OLE) of study C017?

Serratosa, J. M.; (...); Villanueva, V.

Meeting Abstract. 2023


Campos de estudio

Compartir